Drugs / SIBP-A17
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06512116 | Jul 2024 → Jul 2026 overdue | — | Shanghai Institute Of Biological Products | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIBP-A17 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06512116 ↗ |
| Route | Intravenous | “Intravenous infusion administration” NCT06512116 ↗ |